These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 9676832)

  • 1. Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer.
    Iacopetta B; Grieu F; Powell B; Soong R; McCaul K; Seshadri R
    Clin Cancer Res; 1998 Jul; 4(7):1597-602. PubMed ID: 9676832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
    el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
    Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients.
    Berns EM; Klijn JG; Smid M; van Staveren IL; Look MP; van Putten WL; Foekens JA
    Genes Chromosomes Cancer; 1996 Jul; 16(3):170-9. PubMed ID: 8814449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
    Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
    Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
    Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
    Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
    Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
    Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
    Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA
    Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
    Shao ZM; Wu J; Shen ZZ; Nguyen M
    Clin Cancer Res; 2001 Aug; 7(8):2222-7. PubMed ID: 11489795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.
    Berns EM; Klijn JG; van Putten WL; van Staveren IL; Portengen H; Foekens JA
    Cancer Res; 1992 Mar; 52(5):1107-13. PubMed ID: 1737370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
    Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
    Joensuu H; Isola J; Lundin M; Salminen T; Holli K; Kataja V; Pylkkänen L; Turpeenniemi-Hujanen T; von Smitten K; Lundin J
    Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High frequency of G/C transversion on p53 gene alterations in breast cancers from Taiwan.
    Chen FM; Hou MF; Wang JY; Chen TC; Chen DC; Huang SY; Chung YS; Lin SR
    Cancer Lett; 2004 Apr; 207(1):59-67. PubMed ID: 15050734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 mutations occur in aggressive breast cancer.
    Mazars R; Spinardi L; BenCheikh M; Simony-Lafontaine J; Jeanteur P; Theillet C
    Cancer Res; 1992 Jul; 52(14):3918-23. PubMed ID: 1617667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients.
    Falette N; Paperin MP; Treilleux I; Gratadour AC; Peloux N; Mignotte H; Tooke N; Löfman E; Inganäs M; Bremond A; Ozturk M; Puisieux A
    Cancer Res; 1998 Apr; 58(7):1451-5. PubMed ID: 9537247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.
    Thorlacius S; Börresen AL; Eyfjörd JE
    Cancer Res; 1993 Apr; 53(7):1637-41. PubMed ID: 8453635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 alterations are associated with improved prognosis in distal colonic carcinomas.
    Soong R; Grieu F; Robbins P; Dix B; Chen D; Parsons R; House A; Iacopetta B
    Clin Cancer Res; 1997 Aug; 3(8):1405-11. PubMed ID: 9815825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic status of p53 gene mutation in canine mammary carcinoma.
    Wakui S; Muto T; Yokoo K; Yokoo R; Takahashi H; Masaoka T; Hano H; Furusato M
    Anticancer Res; 2001; 21(1B):611-6. PubMed ID: 11299814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.